ASX ANNOUNCEMENT
October 19th, 2011

Presentation at AusBiotech 2011 National Conference

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) advises that the Company is attending the AusBiotech 2011 National Conference in Adelaide, South Australia and that its Chief Executive Officer, Dr. Paul MacLeman, is presenting the attached presentation at the Conference this morning.

FOR FURTHER INFORMATION PLEASE CONTACT

Mr. Thomas G. Howitt
Company Secretary

Genetic Technologies Limited
Phone: +61 3 8412 7000
Highlights

- Established molecular diagnostics business with global reach
- 1st US focused cancer diagnostic launched June 2011
- Supported by in-house US sales and marketing capability
- Targeting accretive growth in cancer management field through M&A
- Underpinned by non-dilutive IP estate and local genetic testing revenue base

Dr Paul MacLeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445
Forward Looking Statements

This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.
Snapshot

- Profitable and cash flow positive financial year 2010/11
  - $18.3M revenues, $900k profit, $2.2m positive cash
- Currently in the 2nd year of a 5 year strategy to build a global cancer diagnostics business
- BREVAGen™ is the first product in this expansion
  - June 2011 USA launch of breast cancer risk test – cheek swab
  - Attractive gross margins and est. $620m pa addressable US market
- Established Australian genetic testing business provides sustaining cash flows and operational base for expansion
  - 1st CLIA certification of Australia laboratory by CMS
- Growing licensing revenues from patent out-licensing
  - Non-coding DNA patent estate: Over 60 licensees/$65m to date
  - 9 licenses granted FY2011 for $13.7m
Oncology Focus

- New technologies driving targeted interventions & extending lives
- Demography and healthcare costs driving growth
- Molecular diagnosis of cancer is most attractive segment of the Dx industry
- Focused market & efficient sales process
- Strong accelerating growth forecast next 4 years
- US & EU export market exposure via BREVAGen™

MDx is the fastest growing segment of the IVD market, led by oncology (34% CAGR)

Source: TSG Partners: Scientia Advisors
Developing a portfolio of tools across cancer management spectrum
Building &/or acquiring products with global protection, application & scope
BREVAGen™

- Novel, validated test for non-familial breast cancer risk, published JNCI Oct2010
- US$600m per annum US market opportunity
- Attractive gross margin - cheek swab
- Launched in 8 initial US territories June2011
- High profile Key Opinion Leaders involved
  - Experts at Stanford, Sloane-Kettering, Dana Farber
- Substantial global opportunity
- Reimbursement and regulatory strategy in place

Dr Paul MacLeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445
BREVAGen™: What does it Mean Clinically?

- BREVAGen™ classifies a woman’s 5 year & lifetime risk of non-familial breast cancer, the commonest variety
- Test combines population risk factors with 7 genetic biomarkers (SNPs) to give an integrated, individual breast cancer risk assessment allowing preventive interventions
- 3,000 patient clinical validation study published JNCI Oct 2010
- Supports existing American Society of Clinical Oncology (ASCO) & American Cancer Society (ACS) treatment guidelines
- Target market 1m intermediate risk biopsy patients p.a., plus approx. 2-300k BRCA ineligible or negative patients p.a. (USA)

Reclassified 64% of all subjects with intermediate Gail scores

- Clinical Risk assessment
  - 30% High Risk
  - 41% Low Risk
- Risk assessment by BREVAGen™
  - 38% High Risk
  - 52% Low Risk

Dr Paul MacLeeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445
Product Portfolio

- Target Discovery and Selection
- Clinical Validation Studies
- Regulatory Review or CLIA
- Launch and Release
- Marker Validation
- Clinical Utility Studies & Publication
- Launch Planning
- Claim Extension Studies

- BRCA/HNPCC/SCN1A (EU/PacRim)
- BREVAGEN™
- Theranostic markers KRAS/BRAF/EGFR (FFPE)
- Partnered Companion Theranostic
- Theranostic markers (circulating)

M&A
- e.g. Breast Cancer
- Prognostic
- Near to market
- ~$300m market

Dr Paul MacLeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445
Licensing: Non-Dilutive Funding Source

- Non-coding DNA patent estate is one of GTG’s core assets
  - 60+ licenses, $65m+ revenue received to date
  - 9 Licenses granted FY2011 to date for total $14m
  - Contracted annuity stream of $5.5m in total to 2015

- Foundational patent families protecting the use of non-coding DNA for genetic analysis
  - ‘179, “Intron Sequence Analysis” 2010
  - ‘762, “Genomic Mapping” 2015
  - ‘033, “Methods for Identifying Matched Groups” 2022
  - ‘589, “Methods for Genomic Analysis” 2022
  - ‘025, “Genetic Analysis Systems and Methods” 2022

- Assertion strategy US (series of formal patent infringement suits)
- Single party negotiations EU & RoW also lucrative
## Financial Snapshot June 2011

### Financials (12 months to Jun30)

<table>
<thead>
<tr>
<th></th>
<th>2011 (AUD millions)</th>
<th>2010 (AUD millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>18.3</td>
<td>8.7</td>
</tr>
<tr>
<td>Operations*</td>
<td>4.6</td>
<td>4.9</td>
</tr>
<tr>
<td>Licensing</td>
<td>13.7</td>
<td>3.8</td>
</tr>
<tr>
<td>Net income / (loss)</td>
<td>0.9</td>
<td>(9.4)</td>
</tr>
<tr>
<td>Cash ‡</td>
<td>5.1</td>
<td>3.3</td>
</tr>
</tbody>
</table>

‡ Institutional placement AUD12.7m July 11
*/*/* Following divestment $750k revenues
** Employee options only

### Share Register

- **Shares outstanding**: 464.6m
- **Top 20 shareholders**: 76%
- **Total shareholders**: 2,850
- **Options outstanding**: 20.7m
- **Market cap (xxx)**: AUDxxm

### Sales A$m – 5 years

<table>
<thead>
<tr>
<th>Year</th>
<th>Operations</th>
<th>Licensing</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>11.3</td>
<td>3.1</td>
</tr>
<tr>
<td>2008</td>
<td>10.8</td>
<td>3.9</td>
</tr>
<tr>
<td>2009</td>
<td>5.4</td>
<td>4.6</td>
</tr>
<tr>
<td>2010</td>
<td>3.7</td>
<td>4.9</td>
</tr>
<tr>
<td>2011</td>
<td>13.7</td>
<td>4.5***</td>
</tr>
</tbody>
</table>

*For personal use only*